Atlas Trials

A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)

Clinical trial NCT01892345 · TERMINATED

Trial details

NCT number
NCT01892345
Sponsor
Alexion Pharmaceuticals, Inc.
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Neuromyelitis OpticaNeuromyelitis Optica Spectrum Disorder
Start date
2014-04-11
Primary completion
2018-07-17
Enrollment
143

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.